Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
Incyte Corporation logo

NYSE · INCY

Incyte Corporation

Healthcare · Biotechnology

$120.39

Up+$3.59 (+3.07%)

Updated Oct 31, 2026, 4:43 PM

SID Score

6.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
18.86B
P/E ratio
15.82
Dividend yield
0.00%
52-week range
$89.25 – $132.60
Volume
2.84M
Avg. volume
2.2M

Price performance · INCY

INCY price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

INCY closed at $120.39 after 21 trading sessions, up 4.41% for the selected period.

Last close
$120.39
Period change
+4.41%
Period low
$108.62
Period high
$120.39
Daily close
View OHLC price history
INCY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$120.10$122.8695$119.55$120.392.84M
Oct 29, 2026$111.64$117.09$111.01$116.803.05M
Oct 28, 2026$115.50$118.49$114.74$116.871.81M
Oct 27, 2026$111.18$116.76$111.18$116.602.23M
Oct 26, 2026$115.485$115.925$112.745$113.312.26M
Oct 23, 2026$116.75$116.865$115.12$115.711.48M
Oct 22, 2026$113.93$117.17$112.76$116.932.24M
Oct 21, 2026$115.98$116.57$113.35$113.441.4M
Oct 20, 2026$113.78$117.00$113.2619$116.6151.34M
Oct 19, 2026$113.19$114.38$112.71$113.251.19M
Oct 16, 2026$113.98$114.57$112.02$113.071.58M
Oct 15, 2026$112.71$116.03$112.60$113.271.94M
Oct 14, 2026$108.61$112.06$107.83$111.571.87M
Oct 13, 2026$111.29$111.675$107.7801$108.622.6M
Oct 12, 2026$114.05$114.05$111.26$111.361.48M
Oct 9, 2026$112.35$113.87$111.805$112.791.12M
Oct 8, 2026$112.89$113.75$110.08$112.751.93M
Oct 7, 2026$112.82$115.49$112.455$113.441.27M
Oct 6, 2026$114.13$114.9651$111.67$112.732.46M
Oct 5, 2026$115.145$115.67$112.83$114.131.95M
Oct 2, 2026$116.76$117.19$114.57$115.302.17M

Latest INCY news

The latest Smart Investors Daily articles mentioning INCY.

Stock researchCompany · Overview

INCY research

Overview

Company profile and research snapshot.

Company profile

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$98.88
Implied upside
—
Analysts
—
INCY recent ratings
DateFirmRatingTarget
Oct 30, 2026RBC CapitalSector Perform—
Oct 30, 2026Wells FargoEqual-Weight—
Oct 30, 2026BarclaysOverweight—
Oct 30, 2026Evercore ISI GroupIn-Line—
Oct 30, 2026OppenheimerOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

Is Incyte (INCY) Cheap After A 120% Three Year Run?

Incyte has logged a strong multi year share price performance, and the question now is whether the business can back up that move with the cash flows needed to justify today’s valuation. Over the past 3 years, Incyte has returned 120.2%, which puts a lot of weight on whether the underlying cash generation truly supports that kind of share price gain. Fresh oncology trial collaborations and upcoming late stage data readouts may shape expectations for how quickly Incyte can turn its pipeline...

Yahoo · Oct 24, 2026

Incyte (INCY) Heads To ESMO With New Oncology Data, Is The Stock Still Undervalued?

Incyte (INCY) is back in focus as it prepares to present new oncology data at the European Society for Medical Oncology Congress in Madrid, covering several high-need solid tumor programs. That interest is landing on a stock that has been choppy in the short term but strong over longer periods, with Incyte’s 30 day share price return down 7.16% even as the year to date move sits at a 14.09% gain and the 3 year total shareholder return reaches 120.23%. This suggests sentiment has cooled...

Yahoo · Oct 23, 2026

Star Therapeutics Announces $200 Million Private Financing to Advance Pipeline of Best-in-Disease Therapies

SOUTH SAN FRANCISCO, Calif., October 23, 2026--Star Therapeutics, a biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced a $200 million private financing. The financing follows the July 2026 acquisition of Star subsidiary Vega Therapeutics and was co-led by OrbiMed and Janus Henderson Investors, with participation from Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Vent

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By